Abstract
Telavancin is an investigational lipoglycopeptide antibiotic that is active against gram-positive pathogens. In an in vivo rabbit model, subtherapeutic (15-mg/kg) and therapeutic (30- or 45-mg/kg) doses of telavancin were demonstrated to be noninferior and superior to vancomycin (20 mg/kg), respectively, for preventing subcutaneous implant colonization and infection by Staphylococcus aureus.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminoglycosides / therapeutic use*
-
Animals
-
Anti-Bacterial Agents / therapeutic use*
-
Catheter-Related Infections / prevention & control*
-
Female
-
Lipoglycopeptides
-
Rabbits
-
Staphylococcal Infections / prevention & control*
-
Vancomycin / therapeutic use*
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Lipoglycopeptides
-
Vancomycin
-
telavancin